Accelerator Production of {sup 225}Ac For Alpha-Immunotherapy

Journal Article · Wed Jun 01 00:00:00 EDT 2011 · AIP Conference Proceedings

DOI:https://doi.org/10.1063/1.3586134· OSTI ID:21513392

Weidner, J W; Nortier, F M; Bach, H T; John, K D; Couture, A; Ullmann, J L; Fassbender, M E; Goff, G S; Taylor, W; Valdez, F; Wolfsberg, L E; Cisneros, M; Dry, D; Gallegos, M; Gritzo, R; Bitteker, L J; Wender, S; Baty, R S ^[1]

---

1. Los Alamos National Laboratory, P.O. Box 1663, Los Alamos, NM 87545 (United States)

{sup 225}Ac has tremendous potential for the treatment of metastatic cancer due to the four alpha-particles emitted during its decay to stable {sup 209}Bi. Additionally, it is one of the few alpha-emitters being considered for clinical trials. The anticipated {sup 225}Ac demand for these trials is expected to far exceed the annual worldwide supply of approximately 1,000 mCi/yr. Consequently, the DOE Office of Science has funded investigations into accelerator-based production of {sup 225}Ac. Existing {sup 232}Th(p,x){sup 225}Ac cross section data indicate that up to 480 mCi/day of {sup 225}Ac could be created by bombarding a thick target of natural thorium with 100 MeV protons at the Los Alamos Isotope Production Facility. To verify these predictions, experiments are underway at the Los Alamos Neutron Science Center to measure the {sup 232}Th(p,x){sup 225}Ac production cross sections for protons in the energy range 40-200 MeV, and at 800 MeV. For 800 MeV protons, preliminary results indicate that the {sup 225}Ac production cross section is 12.4{+-}0.6 mb and the {sup 225}Ra production cross section is 3.2{+-}0.2 mb. Moreover, preliminary results suggest that the {sup 227}Ac production cross section is 16{+-}1 mb. Experiments to measure these same cross sections at proton energies below 200 MeV are planned for the last half of calendar year 2010.

• OSTI ID: 21513392
• Journal Information: AIP Conference Proceedings, Vol. 1336, Issue 1; Conference: CAARI 2010: 21. International Conference on the Application of Accelerators in Research and Industry, Fort Worth, TX (United States), 8-13 Aug 2010; Other Information: DOI: 10.1063/1.3586134; (c) 2011 American Institute of Physics; ISSN 0094-243X
• Country of Publication: United States
• Language: English

Related Subjects

43 PARTICLE ACCELERATORS
ACCELERATION
ACCELERATORS
ACTINIUM 225
ACTINIUM 227
ALPHA PARTICLES
ALPHA SOURCES
BISMUTH 209
CLINICAL TRIALS
CROSS SECTIONS
FORECASTING
IMMUNOTHERAPY
ISOTOPE PRODUCTION
METASTASES
MEV RANGE 100-1000
NEOPLASMS
NEUTRONS
PROTONS
RADIUM 225
SHIELDING
THORIUM 232
ACTINIDE NUCLEI
ACTINIUM ISOTOPES
ALKALINE EARTH ISOTOPES
ALPHA DECAY RADIOISOTOPES
BARYONS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BISMUTH ISOTOPES
CHARGED PARTICLES
DAYS LIVING RADIOISOTOPES
DISEASES
ELEMENTARY PARTICLES
ENERGY RANGE
EVEN-EVEN NUCLEI
EVEN-ODD NUCLEI
FERMIONS
HADRONS
HEAVY NUCLEI
INTERNAL CONVERSION RADIOISOTOPES
ION SOURCES
IONIZING RADIATIONS
ISOTOPES
MEDICINE
MEV RANGE
NUCLEI
NUCLEONS
ODD-EVEN NUCLEI
PARTICLE SOURCES
RADIATION SOURCES
RADIATIONS
RADIOISOTOPES
RADIUM ISOTOPES
SPONTANEOUS FISSION RADIOISOTOPES
STABLE ISOTOPES
TESTING
THERAPY
THORIUM ISOTOPES
YEARS LIVING RADIOISOTOPES